

Prior Authorization Request Form for

Androderm, AndroGel, Natesto, Testim, Testosterone 1.62% gel, Vogelxo



JOHNS HOPKINS
MEDICINE

JOHNS HOPKINS
HEALTHCARE

7231 Parkway Drive, Suite 100, Hanover, MD 21076

USFHP Pharmacy Prior Authorization Form

To be completed by Requesting provider	
Drug Name:	Strength:
Dosage/Frequency (SIG):	Duration of Therapy:

FAX Completed Form and Applicable Progress Notes to: (410) 424-4037

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

Step 1 Medication requested:

Step 2 Please complete patient and physician information (please print):

Patient Name: _____ Physician Name: _____
 Address: _____ Address: _____
 Sponsor ID # _____ Phone #: _____
 Date of Birth: _____ Secure Fax #: _____

Step 3 Please complete the clinical assessment:

1. Is the requested medication being used for female-to-male gender reassignment (endocrinologic masculinization)?	<input type="checkbox"/> Yes SKIP to question 7	<input type="checkbox"/> No Proceed to question 2
2. Is the patient a male who is greater than 17 years of age?	<input type="checkbox"/> Yes Proceed to question 3	<input type="checkbox"/> No STOP Coverage not approved
3. Does the patient have a diagnosis of hypogonadism as evidenced by 2 or more morning total testosterone levels below 300 ng/dL?	<input type="checkbox"/> Yes Proceed to question 4	<input type="checkbox"/> No STOP Coverage not approved
4. Has the provider investigated the etiology of the low testosterone levels and acknowledges that testosterone therapy is clinically appropriate and needed?	<input type="checkbox"/> Yes Proceed to question 5	<input type="checkbox"/> No STOP Coverage not approved
5. Is the patient experiencing symptoms usually associated with hypogonadism?	<input type="checkbox"/> Yes Proceed to question 6	<input type="checkbox"/> No STOP Coverage not approved
6. Has the patient tried Fortesta (testosterone 2% gel) or testosterone 1% gel (AndroGel 1% generic) for a minimum of 90 days AND failed to achieve total serum testosterone levels above 400 ng/dL (labs drawn 2 hours after Fortesta application) AND without improvement in symptoms?	<input type="checkbox"/> Yes Sign and date on page 2	<input type="checkbox"/> No SKIP to question 13
7. Does the patient have a diagnosis of gender dysphoria made by a TRICARE-authorized mental health provider according to most current edition of the DSM?	<input type="checkbox"/> Yes Proceed to question 8	<input type="checkbox"/> No STOP Coverage not approved
8. Is the patient 16 years of age or older?	<input type="checkbox"/> Yes Proceed to question 9	<input type="checkbox"/> No STOP Coverage not approved

Prior Authorization Request Form for
Androderm, AndroGel, Natesto, Testim, Testosterone 1.62% gel, Vogelxo

9. Is the patient a biological female of childbearing potential?	<input type="checkbox"/> Yes Proceed to question 10	<input type="checkbox"/> No SKIP to question 11
10. Is the patient pregnant or breastfeeding?	<input type="checkbox"/> Yes STOP Coverage not approved	<input type="checkbox"/> No Proceed to question 11
11. Has the patient experienced puberty to at least Tanner stage 2?	<input type="checkbox"/> Yes Proceed to question 12	<input type="checkbox"/> No STOP Coverage not approved
12. Does the patient have psychiatric comorbidity that would confound a diagnosis of gender dysphoria or interfere with treatment (for example: unresolved body dysmorphic disorder; schizophrenia or other psychotic disorders that have not been stabilized with treatment)?	<input type="checkbox"/> Yes STOP Coverage not approved	<input type="checkbox"/> No Proceed to question 17
13. Does the patient have a contraindication or relative contraindication to Fortesta or testosterone 1% gel (AndroGel 1% generic) that does not apply to the requested agent?	<input type="checkbox"/> Yes Sign and date below	<input type="checkbox"/> No Proceed to question 14
14. Has the patient experienced a clinically significant skin reaction to Fortesta or testosterone 1% gel (AndroGel 1% generic) that is not expected to occur with the requested agent?	<input type="checkbox"/> Yes Sign and date below	<input type="checkbox"/> No Proceed to question 15
15. Is the request for Androderm or Natesto?	<input type="checkbox"/> Yes Proceed to question 16	<input type="checkbox"/> No STOP Coverage not approved
16. Does the patient require a testosterone replacement therapy that has a low risk of skin-to-skin transfer between family members?	<input type="checkbox"/> Yes Sign and date below	<input type="checkbox"/> No STOP Coverage not approved
17. Does the patient have a contraindication or relative contraindication to Fortesta or testosterone 1% gel (AndroGel 1% generic) that does not apply to the requested agent?	<input type="checkbox"/> Yes Sign and date below	<input type="checkbox"/> No Proceed to question 18
18. Has the patient experienced a clinically significant skin reaction to Fortesta or testosterone 1% gel (AndroGel 1% generic) that is not expected to occur with the requested agent?	<input type="checkbox"/> Yes Sign and date below	<input type="checkbox"/> No Proceed to question 19
19. Is the request for Androderm or Natesto?	<input type="checkbox"/> Yes Proceed to question 20	<input type="checkbox"/> No STOP Coverage not approved
20. Does the patient require a testosterone replacement therapy that has a low risk of skin-to-skin transfer between family members?	<input type="checkbox"/> Yes Sign and date below	<input type="checkbox"/> No STOP Coverage not approved

Step 4 I certify the above is true to the best of my knowledge. Please sign and date:

4

 Prescriber Signature

 Date

[27 July 2022]

For Internal Use Only	
<input type="checkbox"/> Approved:	Duration of Approval: ____month(s)
<input type="checkbox"/> Denied:	Authorized By:
<input type="checkbox"/> Incomplete/Other:	PA#:
Date Faxed to MD:	Date Decision Rendered: